On 2022, Click Therapeutics kicked off the self-funded CT-132 project to build the first evidence-based digital therapeutic for migraine.
As one of the founding designers, I took initiative on hypothesis-driven research and end-to-end design for core features, working alongside our Design Lead, Vanessa Jimenez, as well as my science, product, and engineering counterparts.
With a successful clinical trial that reduced migraine days for 500+ patients, the CT-132 app received FDA authorization in 2024 and became a huge milestone for patients and the industry.
Migraine affects 1+ billion people globally, but existing products lack clinical impact and fail to address daily patient challenges outside symptom tracking.
Tight clinical trial deadlines meant traditional research cycles weren't an option. Regulatory constraints prevented us from testing therapeutic elements with real patients.
Prove that software can deliver measurable health outcomes under FDA scrutiny, and meet non-negotiable clinical trial deadlines that determine the company's outlook.
We started with diving into clinical guidelines and evidence-based treatment protocols. Our clinical team provided the scientific foundation that would drive measurable health outcomes.
We translated clinical requirements into product features and user flows. This involved creating a "micro-dosing" engagement philosophy and designing flexible templates that could adapt to evolving clinical content.
Finally, we executed on the UX design through hypothesis-driven testing. We created three distinct app concepts to understand what type of experience would resonate with migraine patients, then refined based on real user feedback.
While features and content were locked in, we needed to discover what type of app experience would resonate with migraine patients.
We created three concepts that balanced visual style, tone, and narrative differently to test what would feel supportive vs. overwhelming.
Proved digital therapeutics can be both clinically effective and user-friendly.
Showcased design capabilities that attracted partnership inquiries and new opportunities.
First to prove user-centered design can meet FDA regulatory requirements.
• Be adaptive. There are many ways to achieve great design. Choose the design approach that can provide the most actionable insights under the constraints.
• Design is about communication. Designers should help the team connect the dots and be more effective.
• Be comfortable with managing unknowns and constant reprioritization, especially when things are moving in parallel.